Pharmafile Logo
Pharmafocus logo
Advanced Search

Zelboraf

Showing 15 posts of 19 posts found.

roche

FDA approves Roche skin cancer combination

November 11, 2015
Research and Development, Sales and Marketing Cotellic, FDA, Genentech, Roche, Zelboraf, cobimetinib, melanoma, skin cancer, vemurafenib

The FDA has approved the skin cancer drug Cotellic for certain forms of melanoma in combination with another Roche cancer …

News
Zelboraf image

Roche submits melanoma drug to FDA

December 15, 2014
Sales and Marketing Cobimeinib, FDA, Roche, Zelboraf, mekinist, melanoma, taflinlar, vemurafenib

Roche has submitted its melanoma drug cobimeinib for review with the FDA as it confirms the results of its Phase …

News

GSK melanoma drugs beat rival in new study

July 18, 2014
Sales and Marketing GSK, Roche, Tafinlar, Yervoy, Zelboraf, mekinist, melanoma

GlaxoSmithKline’s new combination melanoma treatment has bested Roche’s established oncology drug Zelboraf when treating patients with the deadliest form of …

News
gsk_hq_close

GSK’s Tafinlar/Mekinist combo given FDA priority review status

September 17, 2013
Research and Development, Sales and Marketing GSK, Roche, Tafinlar, Zelboraf, melanoma

News
Zelboraf image

Eight in ten survive skin cancer

July 22, 2013
Research and Development, Sales and Marketing Yervoy, Zelboraf, melanoma, skin cancer

The vast majority of men and women diagnosed with malignant melanoma are now surviving the disease, according to a new …

News
Roche image

Roche’s Erivedge gains conditional EU approval

July 15, 2013
Sales and Marketing Curis, EU, Erivedge, Roche, Swiss, Zelboraf

Roche’s cancer pill Erivedge has received a conditional European approval for treatment of the most common type of skin cancer. …

News
yervoy image

NICE hails ‘breakthrough’ skin cancer treatments

November 2, 2012
Sales and Marketing BMS, NICE, Roche, Yervoy, Zelboraf

Two new skin cancer drugs have been recommended by NICE, which hailed the drugs as ‘breakthrough treatments’. Bristol-Myers Squibb’s Yervoy …

News
yervoy image

BMS highlights Yervoy survival data

October 1, 2012
Research and Development, Sales and Marketing BMS, Roche, Yervoy, Zelboraf

Bristol-Myers Squibb’s melanoma drug Yervoy helps patients survive for longer than if they are receiving standard chemotherapy alone, according to …

News
Zelboraf image

NICE still minded not to recommend Zelboraf

August 9, 2012
Sales and Marketing BMS, NICE, QALY, Yervoy, Zelboraf

NICE is asking Roche for more information about its melanoma pill Zelboraf, saying it is still too expensive and its …

News
GSK image

GSK submits melanoma drugs for regulatory approval

August 3, 2012
Sales and Marketing FDA, GSK, NDA, Zelboraf, melanoma, oncology

GlaxoSmithKline has submitted its two investigational melanoma drugs to regulators in both Europe and the US. The firm is seeking …

News
Roche image

Roche posts strong sales results

July 27, 2012
Sales and Marketing Pegasys, Perjeta, Roche, Zelboraf, dalcetrapib

Roche has published healthy revenue growth for the first half of 2012, but its profits have taken a hit. The …

News
Zelboraf image

Roche’s Zelboraf rejected by NICE

June 15, 2012
Sales and Marketing Cancer, Dillon, NICE, Roche, Zelboraf, melanoma

NICE is not recommending Roche’s targeted melanoma pill Zelboraf because of its high cost and uncertainties over its survival benefit. …

News

GSK starts combination trial for melanoma

May 30, 2012
Research and Development, Sales and Marketing GSK, R&D, Roche, Zelboraf, melanoma

GlaxoSmithKline has begun a combination trial for two of its investigational skin cancer drugs.  The firm will combine dabrafenib, its …

News
Zelboraf image

Roche’s melanoma pill launched in UK

March 14, 2012
Sales and Marketing BMS, CDF, NICE, Roche, Yervoy, Zelboraf

Roche’s Zelboraf has been launched in the UK to treat the deadliest form of skin cancer.  Zelboraf (vemurafenib) is the …

News
caprelsa image

Major new drugs for 2012

March 9, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Caprelsa, Eylea, Manjor new drugs, Xalkori, Zelboraf, avastin, inlyta

 Renal cell carcinoma Pfizer’s Inlyta (axitinib) has been approved as second line treatment for renal cell carcinoma. The drug is …

Feature

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023